Aktienanalyse zu Omeros Corp (OMER)OMEROmeros Corp

Omeros Corporation is a clinical-stage biopharmaceutical company. The Company focuses on discovering, developing, and commercializing first-in-class small-molecule and protein therapeutics for both large-market and orphan indications, with a particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. Its clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program. Its commercial product, YARTEMLEA, is the approved inhibitor of the lectin pathway of complement. YARTEMLEA is used for the treatment of TA-TMA in adults and in children ages two years and older. YARTEMLEA selectively inhibits MASP-2, blocking pathway activation while preserving classical and alternative complement pathway functions. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Omeros Corp is a good buy right now due to its recent strong performance and positive market sentiment. The current price is $19.83, and the stock has shown a remarkable 1-year change of +373.27%. Additionally, the gross margin for Q2 2026 is an impressive 97.20%, indicating strong profitability potential. The main risk is the forward P/E ratio of 87.72, suggesting high expectations that could lead to volatility if future earnings do not meet projections.

7 analysts cover OMER: 6 rate it Buy, 1 Hold and 0 Sell. The average price target is 43.67.